Blakes Breakfast Speaking Event on BioPharma

LifeSciences BC is pleased to announce the November LifeSciences BC Blakes Breakfast Speaking Event on BioPharma for Thursday, November 5. We are pleased to collaborate with BioTalent Canada to present the results of their Connecting and Advancing Women in the Canadian Bio-economy national survey. In celebration of National Biotech Week, we will conclude the event with a networking luncheon.

Time: 7:30 – 8:00 am Registration and Breakfast 8:00 - 9:30 am BioPharma Company Presentations 9:30 – 10:00 am Networking 10:00 - 11:30 am BioTalent Canada Connecting and Advancing Women in Bio 11:30 - 1:00 pm Lunch

Registration for Breakfast: LifeSciences BC members - $45 + GST Non-members - $90 + GST
___________________________________________________________________________

BioPharma Company Presentations:

Nick Glover, Ph.D.

President and Chief Executive Officer

Dr. Glover is an accomplished life sciences professional, with extensive strategic, financial and operational experience in the biotechnology sector, evidenced by demonstrable value creation and successful outcomes. Previously, Dr. Glover served as the President and Chief Executive Officer at YM BioSciences Inc., a publically traded oncology drug development company acquired by Gilead Sciences Inc. in February 2013. YM’s lead drug candidate, momelotinib, was an orally administered JAK inhibitor being developed for the treatment of myelofibrosis and other hematological disorders. Prior to that, Dr. Glover served as the President and Chief Executive Officer of Viventia Bio Inc., a publically traded biopharmaceutical company focused on the development of monoclonal antibody technologies. Dr. Glover also previously served as an investment manager for MDS Capital, a life sciences venture capital firm. He currently serves on the board of directors of MEI Pharma Inc., a company developing novel therapies for hematology and oncology. Dr. Glover holds a B.Sc. (Hons) in chemistry from the University of East Anglia, a M.Sc. in chemistry from the University of British Columbia and a Ph.D. in chemistry from Simon Fraser University.

Chief Executive Officer

Norma Biln has brought strategic and operational execution excellence to each position she has held along her career. Throughout her 22 years in the life sciences she has worked along, built and led teams that have consistently exceeded corporate goals. Norma began her career in clinical research with Pfizer Pharmaceuticals after completing her Bachelor of Science in Physiology at McGill University. She continued her career in several capacities in sales management, marketing and market access with Pfizer Pharmaceuticals, Amgen and Abbott Laboratories where she won several regional and national level awards for top performance in each role. She later joined Stressgen Biotechnologies as Director of Corporate Market Development and Director of Sales and Marketing for Stressgen Bioreagents. Before her role of CEO at Augurex, Norma worked in a senior consulting capacity with Aspreva Pharmaceuticals on Business Development, Commercial and Communications initiatives. Norma holds a Master of Business Administration and is Vice-Chair of the Board of Directors of BioTalent Canada. __________________________________________________________________________________________________________________________________
For more information, please contact:

Sarah Wuertz Events & Office Manager

LifeSciences BC

Email: swuertz@lifesciencesbc.ca